NEW YORK (TheStreet) -- Shares of Nordstrom Inc (JWN) are climbing, up 0.73% to $74.69 in pre-market trading Friday, following the luxury department store's first quarter fiscal 2015 earnings release late Thursday.

For the quarter, Nordstrom earned 66 cents per share on revenue of $3.22 billion.

The department store chain was expected to earn 71 cents per share on revenue of $3.16 billion for the quarter, according to analysts polled by Thomson Reuters.

In the same period of last year, Nordstrom reported earnings of 72 cents per share on sales of $2.93 billion.

Looking ahead, the company reiterated its 2015 outlook. Nordstrom forecasts full-year earnings in a range of between $3.65 per share to $3.80 per share.

Shares closed at $74.15 on Thursday.

Seattle, Wash.-based Nordstrom is a fashion specialty retailer offering designer, luxury and quality apparel, shoes, cosmetics and accessories.

The company operates 262 stores in 35 states nationwide, as well as its e-commerce business through Nordstrom.com and HauteLook.

Separately, TheStreet Ratings team rates NORDSTROM INC as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation:

"We rate NORDSTROM INC (JWN) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins, good cash flow from operations and notable return on equity. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated."

You can view the full analysis from the report here: JWN Ratings Report

JWN ChartJWN data by YCharts

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing